Float Short %

10.02

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

0.05

EPS Last/This Y

1.25

EPS This/Next Y

0.44

Price

99.73

Target Price

141.8

Analyst Recom

1.12

Performance Q

-0.73

Upside

-168.4%

Beta

2.04

Ticker: RYTM

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	RYTM	102.86	0.36	2.83	1153
2026-01-26	RYTM	103.41	0.38	0.00	1172
2026-01-27	RYTM	105.61	0.37	0.00	1185
2026-01-28	RYTM	102.76	0.37	999.99	1189
2026-01-29	RYTM	103.51	0.38	1.82	1198
2026-01-30	RYTM	102.54	0.40	0.52	1218
2026-02-02	RYTM	109.49	0.41	0.14	1334
2026-02-03	RYTM	108.41	0.38	0.00	1399
2026-02-04	RYTM	107.96	0.34	0.00	1513
2026-02-05	RYTM	103.93	0.34	0.02	1519
2026-02-06	RYTM	103.55	0.34	999.99	1525
2026-02-09	RYTM	103.9	0.35	0.00	1536
2026-02-10	RYTM	102.87	0.35	0.25	1536
2026-02-11	RYTM	98.32	0.35	0.16	1531
2026-02-12	RYTM	96.03	0.35	0.00	1554
2026-02-13	RYTM	98.13	0.34	2.63	1567
2026-02-17	RYTM	102.67	0.34	0.43	1565
2026-02-18	RYTM	101.27	0.36	0.41	1583
2026-02-20	RYTM	99.78	0.37	0.01	1612
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	RYTM	102.86	-8.4	-	-3.09
2026-01-26	RYTM	103.41	-8.4	-	-3.09
2026-01-27	RYTM	105.53	-8.4	-	-3.09
2026-01-28	RYTM	102.70	-8.4	-	-3.09
2026-01-29	RYTM	103.64	-8.4	-	-3.09
2026-01-30	RYTM	102.52	-8.4	-	-3.09
2026-02-02	RYTM	109.05	-8.4	-	-3.09
2026-02-03	RYTM	108.25	-8.4	-	-3.09
2026-02-04	RYTM	107.90	-8.4	-	-3.09
2026-02-05	RYTM	103.88	-8.4	-	-3.09
2026-02-06	RYTM	103.57	-8.4	-	-3.09
2026-02-09	RYTM	103.90	-8.4	-	-3.09
2026-02-10	RYTM	102.98	-8.0	-	-3.09
2026-02-11	RYTM	98.50	-8.0	-	-3.09
2026-02-12	RYTM	96.00	-8.0	-	-3.09
2026-02-13	RYTM	97.95	-8.0	-	-3.09
2026-02-17	RYTM	102.58	-8.0	-	-3.09
2026-02-18	RYTM	101.27	-8.0	-	-3.09
2026-02-19	RYTM	103.13	-8.0	-	-3.09
2026-02-20	RYTM	99.73	-8.0	-	-3.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	RYTM	-2.49	6.59	9.95
2026-01-26	RYTM	-2.49	6.71	9.95
2026-01-27	RYTM	-2.49	6.71	9.95
2026-01-28	RYTM	-2.49	6.71	10.08
2026-01-29	RYTM	-2.49	6.71	10.08
2026-01-30	RYTM	-2.46	6.71	10.08
2026-02-02	RYTM	-2.46	6.66	10.08
2026-02-03	RYTM	-2.46	6.66	10.08
2026-02-04	RYTM	-2.46	6.66	10.08
2026-02-05	RYTM	-2.46	6.66	10.08
2026-02-06	RYTM	-2.46	6.66	10.08
2026-02-10	RYTM	-2.55	5.14	10.10
2026-02-11	RYTM	-2.55	5.14	10.02
2026-02-12	RYTM	-2.55	5.14	10.02
2026-02-13	RYTM	-2.70	5.14	10.02
2026-02-17	RYTM	-1.99	3.66	10.02
2026-02-18	RYTM	-1.99	3.66	10.02
2026-02-19	RYTM	-1.99	3.66	10.02
2026-02-20	RYTM	-2.16	3.66	10.02
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.82

Avg. EPS Est. Current Quarter

-0.79

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-2.16

Institutional Transactions

3.66

Beta

2.04

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

18.4

Max Drawdown 5-Year %

-88.5

Target Price

141.8

P/E

Forward P/E

PEG

P/S

38.2

P/B

44.71

P/Free Cash Flow

EPS

-3.1

Average EPS Est. Cur. Y

-3.09

EPS Next Y. (Est.)

-2.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-113.41

Relative Volume

0.85

Return on Equity vs Sector %

-95.9

Return on Equity vs Industry %

-78.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

Rhythm Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 283

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today

news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance

stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market

stock prices RYTM premarket after hours

ticker RYTM fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RYTM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y